Predictive Value of Intracellular HIV-1 DNA Levels During CD4-Guided Treatment Interruption in HIV(+) Patients
| Autor: | Lisa Manzini, Lara Gibellini, Luca Bisi, Cristina Mussini, Vanni Borghi, Sara De Biasi, Milena Nasi, Andrea Cossarizza, Cinzia Del Giovane, Serena Manzini, Marcello Pinti, Roberto D'Amico |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Adult
CD4-Positive T-Lymphocytes Male Anti-HIV Agents T cell Immunology HIV Infections Biology Peripheral blood mononuclear cell Drug Administration Schedule Andrology real time pcr chemistry.chemical_compound HIV DNA Predictive Value of Tests Virology medicine Humans HAART interruption Middle Aged CD4 Lymphocyte Count Treatment Outcome Infectious Diseases Real-time polymerase chain reaction medicine.anatomical_structure chemistry Predictive value of tests DNA Viral HIV-1 Female Million Cells Viral load DNA Intracellular |
| Popis: | The amount of HIV-1 DNA within peripheral blood mononuclear cells is an important marker of viral activity. We studied intracellular HIV-1 DNA content in purified CD4(+) T cells from 28 chronically HIV-1-infected adults with sustained CD4(+) T cell counts (500 cells/microl) and undetectable plasma viral load (50 copies/ml), who underwent CD4-guided treatment interruption (TI). Patients were followed up for 18 months during TI, and for 6 months after treatment resumption (TR). Six naïve HIV(+) patients starting therapy were also enrolled and followed up for 6 months. All patients were studied every 2 months; HIV-1 DNA copy number was quantified with real-time PCR. Considering all patients remaining off-treatment, in the first 18 months of TI, intracellular HIV-1 DNA levels (expressed as Log(10) copies/million cells) remained stable (mean, 3.82 and 3.77 at time 0 and after 18 months, respectively). Similarly, HIV-1 DNA values, either in patients who restarted treatment after TI (time 0, 4.90) or in naïve patients who started treatment for the first time (time 0, 4.37), did not change significantly in the first 6 months of therapy (4.42 and 3.67, respectively). Evaluating HIV-1 DNA variations during the first 2 months of TI, we found that patients with a stable level had a lower risk to reach a CD4(+) T cell count350 cells/microl, and thus to restart therapy, whereas this risk was significantly higher in those with a marked increase of HIV-1 DNA. In conclusion, intracellular HIV-1 DNA is a predictive marker for the length of CD4-guided TI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|